:Diphenylbutylpiperidine

{{Short description|Class of typical antipsychotic drugs}}

Image:Diphenylbutylpiperidines skeletal.svg

Diphenylbutylpiperidines are a class of typical antipsychotic drugs which were all synthesized, developed, and marketed by Janssen Pharmaceutica.{{cite journal | vauthors = Galizzi JP, Fosset M, Romey G, Laduron P, Lazdunski M | title = Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 83 | issue = 19 | pages = 7513–7 |date=October 1986 | pmid = 2429309 | pmc = 386749 | doi = 10.1073/pnas.83.19.7513| doi-access = free | bibcode = 1986PNAS...83.7513G }}{{cite journal | vauthors = Qar J, Galizzi JP, Fosset M, Lazdunski M | title = Receptors for diphenylbutylpiperidine neuroleptics in brain, cardiac, and smooth muscle membranes. Relationship with receptors for 1,4-dihydropyridines and phenylalkylamines and with Ca2+ channel blockade | journal = European Journal of Pharmacology | volume = 141 | issue = 2 | pages = 261–8 |date=September 1987 | pmid = 2445589 | doi = 10.1016/0014-2999(87)90271-8}}

They include:

• Clopimozide (R-29,764)
• Fluspirilene (Redeptin)
• Penfluridol (Semap, Micefal, Longoperidol)
• Pimozide (Orap)

A closely related antipsychotic, amperozide, has an additional nitrogen atom in the heterocyclic ring and is classified as a diphenylbutylpiperazine.{{cite book | doi = 10.1016/S0378-6080(05)80189-8 | title = Antipsychotic drugs | series = Side Effects of Drugs Annual | date = 1993 | last1 = Figueras | first1 = Albert | last2 = Capellà | first2 = Dolors | volume = 17 | pages = 49–71 | isbn = 978-0-444-82005-1 }}